Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 2
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Mucormycosis is an invasive fungal disease caused by saprophytic molds and is characterized by a fulminant course and high mortality. Reported increase of disease cases and more frequent mucormy-cosis superinfections in COVID-19 patients are of a serious concern. Head and neck area is the most typical location of mucormycosis and often the first symptoms are eminent in oral cavity, therefore a dentist may be the first healthcare practitioner to recognize signs of this dangerous and potentially fatal disease. Urgent diagnosis and implementation of appropriate treatment are essential for the patient’s survival. The dentist’s participation in postoperative care is necessary and due to the destructive nature of radical surgical treatment, prosthetic rehabilitation is required to improve the patient’s function and quality of life. Furthermore the vigilance of dentists will also allow early recognition of frequent recur-rences of this insidious infection.
Go to article

Bibliography

1. Nilesh K., Vande A. V.: Mucormycosis of maxilla following tooth extraction in immunocompetent patients: reports and review. J Clin Exp Dent. 2018; 10 (3): e300.
2. Paultauf A.: Mycosis mucorina. Ein Beitrag zur Kenntniss der menschlichen Fadenpilzerkrankungen. Arch Path Anat. 1885, 102 (3): 543–564.
3. Cornely O. A., Alastruey-Izquierdo A., Arenz D., et al.: Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet Infect Dis. 2019; 19 (12): e405–e421.
4. Sikora M., Małecka M., Stąpor A., et al.: Mucormycosis of the maxillary sinus in an immunocompetent woman with oro-antral fistula — a case report. Pomeranian Journal of Life Sciences. 2021; 67 (1): 32– 37.
5. Rawlani S.S., Siddiqui A., Reza M., et al.: Black Fungus Mucormycosis, Epidemiology, Etiopathogenesis, Clinical Diagnosis, Histopathology and its Management — A Review. Int J Med Dent Res. 2021; 1 (2): 01–08.
6. Serris A., Danion F., Lanternier F.: Disease entities in mucormycosis. Journal of Fungi. 2019; 5 (1): 23.
7. Ahmadikia K., Hashemi S.J., Khodavaisy S., et al.: The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. 2021; 64 (8): 798–808.
8. Prakash H., Chakrabarti A.: Global epidemiology of mucormycosis. Journal of Fungi. 2019; 5 (1): 26.
9. Jeyaraj P.: Sino-Maxillary Mucormycosis of Iatrogenic Etiology in an Immunocompetent Patient- Importance of Early Diagnosis and Prompt Management. Journal of Infectious Diseases & Case Reports. 2021; 2 (1): 1–8. https://doi.org/10.47363/JIDSCR/2021.
10. Kiralj A., Nalić B., Brajković D.: Management of fulminant mucormycosis of maxillary sinus and orbit with uncontrolled diabetic. Srpski arhiv za celokupno lekarstvo. 2021; 149 (3–4): 225–228. https://doi.org/10.2298/SARH200604015K.
11. Viterbo S., Fasolis M., Garzino-Demo P., et al.: Management and outcomes of three cases of rhinocerebral mucormycosis. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod. 2011; 112 (6): e69–e74.
12. Martínez-Herrera E., Julián-Castrejón A., Frías-De-León M.G., et al.: Rhinocerebral mucormycosis to the rise? The impact of the worldwide diabetes epidemic. Anais Brasileiros de Dermatologia. 2021; 96: 196–199.
13. Bansal D., Pandey A.K., Bhardwaj A., et al.: Extra-Rhino Cerebral Manifestations of Mucormycosis in Head and Neck Region: An Insight. Indian Journal of Otolaryngology and Head & Neck Surgery. 2021; 1–6. https://doi.org/10.1007/s12070-021-02440-z.
14. Honavar S.G.: Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito- Cerebral Mucormycosis in the Setting of COVID-19. Indian Journal of Ophthalmology. 2021; 69 (6): 1361–1365. https://doi.org/10.4103/ijo.IJO_1165_21.
15. Prabhu S., Alqahtani M., Al Shehabi M.: A fatal case of rhinocerebral mucormycosis of the jaw after dental extractions and review of literature. Journal of Infection and Public Health. 2018; 11 (3): 301–303.
16. Karthik S., Shanmugam A., Dhinakaran E.C., et al.: Mucormycosis. Case report and literature review. Hel Arch Oral & Max Fac Surg. 2021; 21 (1): 37–41.
17. Srivastava A., Mohpatra M., Mahapatra A.: Maxillary fungal osteomyelitis: A review of literature and report of a rare case. Annals of Maxillofacial Surgery. 2019; 9 (1): 168.
18. Ketenci İ, Ünlü Y., Kaya, et al.: Rhinocerebral mucormycosis: Experience in 14 patients. The Journal of Laryngology & Otology. 2011; 125 (8): E3. doi: 10.1017/S0022215111000843.
19. Prakash H., Chakrabarti A.: Epidemiology of Mucormycosis in India. Microorganisms. 2021; 9: 523.
20. Nishanth D.G., Anitha D.N., Babu D.N.A., et al.: Mucormycosis — A Review. European Journal of Molecular & Clinical Medicine. 2020; 7 (3): 1786–1791.
21. Suganya R., Malathi N., Karthikeyan V., et al.: Mucormycosis: a brief review. J Pure Appl Microbiol. 2019; 13 (1): 161–165.
22. Maini A., Tomar G., Khanna D., et al.: Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep. 2021; 82: 105957.
23. Pandiar D., Kumar N.S., Anand R., et al.: Does COVID 19 generate a milieu for propagation of mucormycosis? Med Hypotheses. 2021 Jul; 152: 110613. doi: 10.1016/j.mehy.2021.110613. PMID: 34087613; PMCID: PMC8152198.
24. Doni B.R., Peerapur B.V., Thotappa L.H., et al.: Sequence of oral manifestations in rhino-maxillary mucormycosis. Indian J Dent Res. 2011; 22 (2): 331.
25. Fouad Y.A., Abdelaziz T.T., Askoura A., et al.: Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic. Front Med (Lausanne). 2021; 8: 645270. Published 2021 May 28. doi: 10.3389/fmed.2021.645270.
26. Banerjee M., Pal R., Bhadada S.K.: Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India. Postgrad Med J. 2021 Jun 8. doi: 10.1136/postgradmedj-2021-140537. Epub ahead of print. PMID: 34103372.
27. Reddy S.G., Kumar K.K., Sekhar C.P., et al.: Oral Mucormycosis: Need for early diagnosis! J NTR Univ Health Sci. 2014; 3: 145–147.
28. Dadhich A., Nilesh K., Patil R., et al.: Unusual presentation of mucormycosis mimicking a localised sino-orbital pathology. BMJ Case Reports CP. 2021; 14 (1): e239199.
29. Godinho G., Abreu I., Alves G., et al.: Orbital Apex Syndrome due to Orbital Mucormycosis after Teeth Infection: A Successful Case Report. Case Reports in Ophthalmology. 2021; 12 (1): 110–115.
30. Nicolatou-Galitis O., Sachanas S., Drogari-Apiranthitou M., et al.: Mucormycosis presenting with dental pain and palatal ulcer in a patient with chronic myelomonocytic leukaemia: case report and literature review. JMM Case Reports. 2015; 2 (1): e000014.
31. Lupoi D., Preda M.: Fungal rhinosinusitis between regular infection and aggressive life-threatening disease. Journal of Contemporary Clinical Practice. 2020; 6 (2): 86–92.
32. Santosh A.B.R., Muddana K., Bakki S.R.: Fungal infections of oral cavity: diagnosis, management, and association with COVID-19. SN Compr Clin Med. 2021; 3: 1373–1384.
33. Bonifaz A., Tirado-Sánchez A., Paredes-Farrera F., et al.: Oral involvement in mucormycosis. A retrospective study of 55 cases. Enferm Infecc y Microbiol Clín. (English ed.) 2020. S0213-005X (20) 30293-7.
34. Gupta D.K., Gupta D.K., Gupta N.: Dental Complications After Covid-19 Mucormycosis?? Under-standing The Pathophysiology. Guident. 2021 Mar; 14 (4): 26–29.
35. Kwak E.J., Kim D.J., Nam W., Park W.: Mucormycosis in the Jaw: A Report of 2 Cases and Literature Review. Oral Health & Preventive Dentistry. 2020; 18 (1): 1011–1016. https://doi.org/10.3290/j.ohpd.a45522.
36. Brunet K., Rammaert B.: Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Méd. 2020; 30 (3): 101007.
37. Panneerselvam K., Kumar M.S., Karthikeyan A.: Recurrent mucormycosis — Better understanding of treatment and management. J Family Med Prim Care. 2020; 9 (12): 6279.
38. Gaur V., Patel K., Pałka Ł.: An implant-supported prosthetic rehabilitation of a patient with a bilateral subtotal maxillectomy defect secondary to rhino-orbital-cerebral mucormycosis: A clinical report of a graftless approach. J Prosthet Dent. 2021 Feb 4: S0022-3913(21)00005-6. doi: 10.1016/j.prosdent.2020.12.022.Epub ahead of print. PMID: 33551135.
Go to article

Authors and Affiliations

Marcin Pasternak
1
Rafał Olszanecki
1

  1. Chair of Pharmacology, Jagiellonian University Medical College, Kraków, Poland
Download PDF Download RIS Download Bibtex

Abstract

Background: Preeclampsia (PE) is a condition characterized by high blood pressure and significant proteinuria in pregnant women. It affects about 7% pregnancies and can be cause of fetal and maternal morbidity and mortality. During pregnancy, a physiological overexpression of the Renin-An-giotensin System (RAS) components is observed, including increased plasma Ang II level. Dysregulation of RAS in placenta may contribute to preeclampsia and uterine growth retardation. The aim of the study was to evaluate the Ang I metabolism in human preeclamptic placentas and to compare to normal pregnancies condition.
Method: Fragments of placental tissues were collected right after ceasarian section from PE and phy-siological pregnancies. Tissues were incubated in Krebs buffer in the presence of Ang I. Evaluation of Ang I metabolites in incubating fluid was performed by LC/MS/MS method. mRNA expression of main RAS components was measured by RT-PCR.
Results: Pattern of angiotensin metabolites did not differ between groups. The main products were Ang 1–7 and Ang II. Comparing to control group, more than 3-fold lower production of Ang II and Ang 1–7 in preeclampsia was observed. mRNA expressions of ACE and AT1 were significantly decreased in pre-eclamptic placentas, whereas higher expression of mRNA of ACE2 and MAS receptor were observed.
Conclusions: Production of Ang 1–7 by PE placentas was significantly lower than in control group. Significantly decreased mRNA expression of ACE and AT1 receptor and lower production of Ang II in placentas of PE patients suggest that placental Ang II/ACE/AT1r pathway could be less important than Ang 1–7/ACE-2/MASr pathway in development of preeclampsia, but this requires further investigations.
Go to article

Authors and Affiliations

Dominika Stettner-Kołodziejska
1
Beata Bujak-Giżycka
2
Anna Wiśniewska
3
Magdalena Łomnicka
3
Michał Kołodziejski
1
Marcin Wiecheć
1
Krzysztof Rytlewski
1
Hubert Huras
1
Rafał Olszanecki
3

  1. Chair of Gynecology and Obstetrics, Jagiellonian University Medical College, Kraków, Poland
  2. Department of Clinical Pharmacology, Jagiellonian University Medical College, Kraków, Poland
  3. Chair of Pharmacology, Jagiellonian University Medical College, Kraków, Poland

This page uses 'cookies'. Learn more